Stock IMGN IMMUNOGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases ImmunoGen, Inc.

Equities

IMGN

US45253H1014

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbbVie Completes Acquisition of ImmunoGen
PR
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLY
PR
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
BU
FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer
AQ
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
BU
IMMUNOGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ImmunoGen, Inc. - IMGN
BU
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio
AQ
Shareholder Alert: Ademi LLP investigates whether ImmunoGen, Inc. has obtained a Fair Price in its transaction with AbbVie
PR
IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders
BU
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
PR
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference
BU
ImmunoGen: Q3 Earnings Snapshot
AQ
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
BU
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMGN Stock
  4. News ImmunoGen, Inc.
  5. Press Releases